Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical and Experimental Nephrology

• Publication date

  2011-08-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10157-011-0512-3PMID 21823043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

  2010cited by this paper
• Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

  2010influential reference
• Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

  2010cited by this paper
• Revised equations for estimated GFR from serum creatinine in Japan.

  2009cited by this paper
• Angiotensin inhibition stimulates PPARγ and the release of visfatin

  2008cited by this paper
• Rosiglitazone decreases albuminuria in type 2 diabetic patients.

  2007cited by this paper
• Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes.

  2007cited by this paper
• Renoprotection Provided by Losartan in Combination with Pioglitazone Is Superior to Renoprotection Provided by Losartan Alone in Patients with Type 2 Diabetic Nephropathy

  2007cited by this paper
• Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.

  2006cited by this paper
• Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

  2006cited by this paper
• Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

  2006cited by this paper
• Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.

  2006cited by this paper
• Insulin-Mediated Upregulation of the Renin Angiotensin System in Human Subcutaneous Adipocytes Is Reduced by Rosiglitazone

  2005cited by this paper
• Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

  2005influential reference
• Effects of Pioglitazone and Metformin on the Development of Hypertension and on Insulin Sensitivity in 1 K 1 C Rats

  2005cited by this paper
• Anti‐inflammatory Effect of PPARγ in Cultured Human Mesangial Cells

  2004cited by this paper
• Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity

  2004cited by this paper
• One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

  2004cited by this paper
• Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

  2004cited by this paper
• Anti-inflammatory effect of PPARgamma in cultured human mesangial cells.

  2004cited by this paper
• Rosiglitazone reduces urinary albumin excretion in type II diabetes

  2003cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.

  2001cited by this paper
• Transcriptional Suppression of Type 1 Angiotensin II Receptor Gene Expression by Peroxisome Proliferator-Activated Receptor-γ in Vascular Smooth Muscle Cells.

  2001cited by this paper
• Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.

  2000cited by this paper
• Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

  1994cited by this paper
• Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

  1984cited by this paper

• The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions

  2025cites this paper
• Thiazolidinediones for people with chronic kidney disease and diabetes.

  2025cites this paper
• Metformin for preventing the progression of chronic kidney disease.

  2024cites this paper
• Pioglitazone in diabetic kidney disease: forgotten but not gone

  2022influential citation
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2022cites this paper
• Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

  2021cites this paper
• Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.

  2019cites this paper
• Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

  2019cites this paper
• Effects of Pioglitazone and Irbesartan on Endothelial Dysfunction on Experimentally Streptozotocin-Induced Diabetic Nephropathy in Rats

  2018cites this paper
• Recent Advances in Management of Diabetic Nephropathy

  2017cites this paper
• Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis

  2017cites this paper
• The current role of thiazolidinediones in diabetes management

  2016cites this paper
• PPAR agonists in the treatment of diabetes

  2015cites this paper
• Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

  2015cites this paper
• Pioglitazone: lessons and learnings 15 years since launch and beyond

  2015cites this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cites this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cites this paper
• Treatment of albuminuria due to diabetic nephropathy: recent trial results

  2014cites this paper
• Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney

  2014influential citation
• Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria

  2013influential citation
• The effect of hydrochloride pioglitazone on urinary 8-hydroxy -deoxyguanosine excretion in type 2 diabetics.

  2013cites this paper